MinervaX ApS, a privately held Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS), today announces the appointments of Jamila Louahed as Chief Development Officer and Hans Henrik Chrois Christensen as Chief Financial Officer. These appointments strengthen MinervaX’s capabilities as the company advances its novel GBS vaccine toward pivotal trial initiation in the maternal indication and continues to scale its operations.

Press inquiries should be adressed to: